Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Invitae

There high-quality healthcare stocks are at fire-sale prices today.

Got $300? These 3 Stocks Could Be Bargain Buys for 2022 and Beyond

NEW BRUNSWICK, N.J. , March 9, 2022 /PRNewswire/ -- Revelations that Johnson & Johnson (NYSE: JNJ) paid scientific researchers to conduct unethical and inhumane experiments on prisoners in the 1960s are shedding new light on what the company knew about cancer risks from its talc-based products like the iconic Johnson's Baby Powder, just as the company is moving to shut down jury trials in a controversial bankruptcy gambit.

Talc-Cancer Lawsuits Play Critical Role in Exposing Johnson & Johnson's Unethical Experiments on Prisoners

AbbVie

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

What's in Store for These 3 Big Pharma Outperformers in 2022?

Pfizer

2 Dividend Stocks to Buy and Hold for the Long Term

Johnson & Johnson's (JNJ) Management Presents at Raymond James 43rd Institutional Investors Conference (Transcript)

Diamondback Energy

Home Depot

Coca-Cola

Should you rotate into dividend stocks amid the looming hike in interest rates?

4 Top Dividend Stocks To Watch In March 2022

Johnson & Johnson (JNJ) closed at $172.21 in the latest trading session, marking a +1.61% move from the prior day.

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

Johnson & Johnson (JNJ) Management at 42nd Annual Cowen Health Care Conference (Transcript)

Johnson & Johnson (JNJ) finally solved its long-term talc-related litigations by spinning off its Consumer Health segment and declaring it bankrupt.

Johnson & Johnson: Your 101 Guide To Litigation Protection - Bankruptcy

A well-diversified business that is poised to grow for a long time could be your smartest pick this year.

3 Reasons This HealthCare Stock Is a Great Buy in 2022

Though less effective than Pfizer's shot, the risk of hospitalization is still significantly higher for unvaccinated people.

Risk Of Covid Hospitalization 5 Times Higher With Johnson & Johnson Shot Than Pfizer

Intuitive Surgical

Look for growing companies in evolving sectors if you are just entering the investing world.

New Investor? Consider Buying These 2 Unstoppable Growth Stocks

Innovative Industrial Properties

Pinterest

Diversifying is a smart way of investing!

The Smartest Stocks To Buy With $1,000 Right Now

Bristol-Myers

Partners Johnson & Johnson ( JNJ , Financial) and Legend Biotech Corp. ( LEGN , Financial) would probably agree that good things come to those who wait. The two pharma companies were rewarded for their patience when the Food and Drug Administration approved their CAR-T therapy this week.

Johnson & Johnson's Gain Could Be Bristol-Myers' Loss

Legend Biotech

The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma. The approval covers adult patients who have received four or more prior lines of therapy, including a.

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

Wall Street closed sharply higher on Friday investors continued to assess the financial risks related to the geopolitical conflict between Russia and Ukraine.

Stock Market News for Feb 28, 2022

It's one of the largest settlements in U.S. history.

Johnson & Johnson And Drug Distributors Finalize $26 Billion Settlement To End Opioid Crisis Lawsuits

Johnson & Johnson (NYSE: JNJ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible.

Johnson & Johnson Sees A Strong Move: Is It Ready For A Breakout?

(Reuters) -A U.S. judge ruled on Friday that a Johnson & Johnson subsidiary can remain in bankruptcy, preventing plaintiffs from pursuing 38,000 lawsuits against the company alleging its baby powder and other talc products cause cancer.

Judge allows Johnson & Johnson talc unit to remain in bankruptcy court

Drugmaker Johnson & Johnson and three major distributors finalized nationwide settlements over their role in the opioid addiction crisis Friday, an announcement that clears the way for $26 billion to flow to nearly every state and local government in the U.S.

J&J, distributors finalize $26B opioid settlement

Settlements represent largest of opioid-related cases in epidemic that has killed more than 500,000 Americans over two decades

J&J and distributors to pay $26bn to settle claims they fuelled US opioid crisis

The three largest U.S. drug distributors and drugmaker Johnson & Johnson have agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments that they helped fuel the U.S. opioid epidemic.

Drug distributors, J&J agree to finalize $26 billion opioid settlement

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Down 4.3% Since Last Earnings Report: Can It Rebound?

Blackrock Inc

Clorox

Procter & Gamble

T. Rowe Price Group

Unilever

In the midst of the uncertainty surrounding the Ukraine conflict, investors are becoming increasingly certain that the stock markets are facing a turning point. It is therefore only right that investors look particularly critically at companies with low growth momentum, poor management, and high debt.

News for Johnson & Johnson Stock (JNJ)